Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg lowers target price on Eurocell following H1 numbers

(Sharecast News) - Analysts at Berenberg lowered their target price on building materials supplier Eurocell from 300p to 270p on Thursday after the group's interim results revealed that subdued end-markets had continued. The German bank noted that overall revenue showed some 10% growth year-on-year, primarily on the back of its Alunet acquisition, and adjusted underlying earnings had grown by 9% to £10.1m.

However, Berenberg noted that Eurocell management continues to highlight the subdued broader trading conditions in UK end-markets, as well as continuing macro uncertainty. As such, it indicated that it now views the FY25 outlook as being below its previous expectations.

"We update our numbers for these results, with our adjusted EBITDA numbers falling by 5-8% across the forecast period, although by more further down the income statement," said Berenberg, which kept its 'buy' rating on the stock.

"We would highlight that these subdued market conditions have been flagged by several peers in the space in recent weeks and that delivering on our updated numbers would still result in the business ultimately delivering flat organic revenues, gross margins and overheads in FY25 against a tough backdrop."

Berenberg added that Eurocell currently trades on a 9.4x FY25 price-to-earnings ratio, 4.4x EBITDA and 9.5x EBIT.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.